Pay to Marwadi

Company Profile

MARKSANS PHARMA LTD.

NSE : MARKSANSBSE : 524404ISIN CODE : INE750C01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE151.550.7 (+0.46 % )
PREV CLOSE (Rs.) 150.85
OPEN PRICE (Rs.) 153.60
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 52856
TODAY'S LOW / HIGH (Rs.)149.80 153.70
52 WK LOW / HIGH (Rs.)69.52 179.1
NSE151.90 0.9 (+0.6 % )
PREV CLOSE(Rs.) 151.00
OPEN PRICE (Rs.) 152.45
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 151.90 (82 )
VOLUME 697149
TODAY'S LOW / HIGH(Rs.) 149.75 153.80
52 WK LOW / HIGH (Rs.)69.55 179.3

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.33
TTM EPS (Rs.) 2.62
P/E Ratio 57.92
Book Value (Rs.) 26.24
Face Value (Rs.) 1
MCap (Rs. in Mn) 68676.97
Price/Earning (TTM) 47.78
Price/Sales (TTM) 8.79
Price/Book (MRQ) 5.78
PAT Margin (%) 14.79
ROCE (%) 14.27
Incorporation Year : 1992

Management Info :

Mark Saldanha - Chairman Mark Saldanha - Managing Director

Registered Office :

Address : 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (W),
Mumbai,
Maharashtra-400053

Phone : 022- 40012000

Registrar's Details : Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE
NEWS More
08Jan01-08-2024$Marksans Pharma informs about compliance certificate Marksans Pharma informs abou
Marksans Pharma has informed that it enclosed Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended December 31, 2023 has been attached.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma has informed that it enclosed Certificate under..
02Jan01-02-2024$Marksans Pharma informs about issuance of duplicate share certificate Marksans Pharma informs abou

Marksans Pharma has informed that it received one request from a shareholder for issue of duplicate share certificate in lieu of the lost/ misplaced original Share Certificate. Its Registrar and Transfer Agent - Bigshare Services has received the completed documents for issuing duplicate share certificate on January 01, 2024 and pursuant to Regulation 39 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, duplicate share certificate is being issued as per details enclosed. 

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma has informed that it received one request from..
22Dec12-22-2023$Marksans Pharma informs about issuance of duplicate share certificates Marksans Pharma informs abou

Marksans Pharma has informed that it has received intimation from its Registrar and Transfer Agent, Bigshare Services today December 21, 2023 regarding the duplicate share certificates of the Company that have been issued, the details of which are enclosed. Pursuant to the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022; a letter of confirmation will be issued to the securities holder / claimant upon completion of necessary procedures regarding duplicate share certificates.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma has informed that it has received intimation fr..
06Nov11-06-2023$Marksans Pharma’s arm receives Marketing Authorisation for product Cyanocobalamin Marksans Pharma’s arm rece

Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA. Earlier, the company’s wholly owned subsidiary -- Time-Cap Laboratories, Inc. had received Establishment Inspection Report (EIR) from US Food & Drugs Administration (USFDA) for audit conducted in October 2023. No 483's were issued during the Audit. 

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma’s wholly owned subsidiary -- Relonchem has re..
06Nov11-06-2023$Marksans Pharma informs about press release Marksans Pharma informs abou
Marksans Pharma has informed that its wholly owned subsidiary Relonchem has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.

The above information is a part of company’s filings submitted to BSE.
Marksans Pharma has informed that its wholly owned subsidiary R..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit252.871028.66
Gross Profit 345.99 1320.35
Operating Profit 4331523.85
Net Sales 2413.646552.04
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap ( in Cr)
57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap ( in Cr)
18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap ( in Cr)
102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap ( in Cr)
91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap ( in Cr)
32917.29
Shareholding Pattern More
PROMOTERS 43.85 %
NON-INSTITUTION 35.83 %
MUTUAL FUNDS/UTI 3.82 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes